Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Ltd ADR (NQ: CNTB )

1.000 +0.010 (+1.01%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,818
Open 1.040
Bid (Size) 0.9800 (8)
Ask (Size) 1.180 (6)
Prev. Close 0.9900
Today's Range 0.9900 - 1.040
52wk Range 0.6777 - 2.660
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
David Szekeres, President of Connect Biopharma Holdings Limited (NASDAQ: CNTB), to Present at NobleCon20
Via Investor Brand Network
Attovia Therapeutics Appoints Chief Financial Officer
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer 
From Attovia Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-18.70%
-18.70%
1 Month
-15.61%
-15.61%
3 Month
-1.96%
-1.96%
6 Month
-41.52%
-41.52%
1 Year
-10.71%
-10.71%

More News

Read More
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal
Via Talk Markets
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal
Via Talk Markets
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.